Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...
Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...
GlobalData on MSN3d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useLenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...
Research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for Gilead Sciences in a report ...
At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...
Gilead Sciences's GILD short percent of float has fallen 8.91% since its last report. The company recently reported that it ...
Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.
Fintel on MSN3d
Deutsche Bank Upgrades Gilead Sciences (GILD)Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...
The board of Gilead Sciences, Inc. (NASDAQ:GILD) has announced that the dividend on 28th of March will be increased to $0.79, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback